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Abstract
How the genomic features of a patient’s cancer relate to individual disease kinetics remains poorly 
understood. We leveraged the indolent growth dynamics of chronic lymphocytic leukaemia (CLL) 
to analyse growth rates and genomic patterns of leukaemia cells from 107 CLL patients, spanning 
decades-long disease courses. We found that CLL commonly demonstrates not only exponential 
expansion but also logistic growth, which is sigmoidal and reaches a certain steady state level. 
Each growth pattern was associated with marked differences in genetic composition, pace of 
disease progression and extent of clonal evolution. In a subset of patients, whose serial samples 
underwent next-generation sequencing, we found that dynamic changes in the CLL disease course 
were shaped by the genetic events that were already present in earliest indolent stages. Finally, by 
analysing growth rates of subclones compared to their parental clones, we quantified the growth 
advantage conferred by putative CLL drivers in vivo.
Keywords
Chronic lymphocytic leukaemia; CLL; clonal evolution; cancer growth dynamics; cancer genetics; 
carrying capacity; cancer growth rate; logistic growth
Introduction
Although we have gained a wealth of knowledge from recent genomic characterization of 
cancer, the linking of genetic features of individual cancers with their phenotype has been 
Gruber et al. Page 2
Nature. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
largely lacking. The rate and pattern of growth can vary amongst cancer patients, and 
various growth patterns have been used to describe cancer expansion1–10. The two most 
commonly used models are exponential unbounded growth and sigmoidal growth, which 
stabilizes at a specific carrying capacity (e.g. logistic growth). However, to date, validations 
of cancer growth patterns have either relied on samples with few data points per tumour or 
have come from in vitro or murine studies.
Chronic lymphocytic leukaemia (CLL) is an informative model system for studying natural 
cancer growth, as it has a highly variable but often relatively indolent course, with treatment 
commonly withheld for months to decades until clinically necessary11. Temporally dense 
tumour measurements are feasible through serial venipuncture, enabling the analysis of 
growth dynamics. The availability of highly pure tumour samples has already yielded rich 
unbiased genetic characterization, leading to our current detailed understanding of genomic 
attributes in CLL12–16. Herein, we undertake an integrative analysis of genetic data, clinical 
information, and growth dynamics, including quantification of the effect of cancer mutations 
on growth rates measured in serial samples collected from 21 patients prior to therapy. We 
then corroborated the results in 86 independent CLL patients, improving our understanding 
of the relationship between genotypes and phenotypes in cancer. Thus, we established a 
methodology and quantitative framework to model cancer growth observed directly from 
human patients, helping explain the variation in the clinical behaviour of CLL.
Results
Distinguishable patterns of growth and genetic evolution in CLL
We identified 21 CLL patients with serial samples collected between diagnosis and first 
treatment (Supplementary Table 1a). Time to initiation of treatment ranged from 2.1 to 15.6 
(median 5.7) years. The cohort was balanced for the strong prognostic marker of IGHV 
mutational status (Methods)17. To assess the overall growth of the leukaemia in each patient, 
we evaluated 4 to 83 (median 22) pre-treatment measurements of peripheral white blood cell 
(WBC) counts per patient. A subset of patients exhibited bounded growth, with WBC counts 
plateauing over time, suggesting the leukaemia displays logistic-like behaviour, while 
another distinct subset clearly demonstrated an exponential-like growth pattern (Extended 
Data Figure 1b, Figures 1a-b). We therefore devised a unified Bayesian model based on a 
logistic pattern, as it can model both predominant growth behaviours. In this context, growth 
rate r and carrying capacity (K) were estimated using a Markov Chain Monte Carlo 
(MCMC) Gibbs sampler (Methods). Patient WBC dynamics that resulted in carrying 
capacity posteriors confidently below 1000 × 109 cells/L were classified as exhibiting 
logistic (LOG) growth, while those confidently above 1000 × 109 cells/L were categorized 
as displaying exponential-like (EXP) growth. Those cases that could not be confidently 
attributed to either of the categories were classified as having indeterminate (IND) growth 
patterns.
Using this classification scheme, five patients exhibited LOG growth behaviour, with 
stabilization at estimated carrying capacities (CC) of 71 to 264 × 109 cells/L (Methods). In 
10 patients, the CLL cells exhibited EXP growth, with growth rates of 14% to 99% relative 
population increase per year (median: 48%/year). Finally, in 6 patients, CLL growth could 
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not be categorized with certainty as either LOG or EXP, either because of the short period of 
observation (Pts 12, 17) or complex patterns of growth (Pts 7, 8, 10 15) (Extended Data 
Figure 1c, Supplementary Table 1). CLLs with LOG growth tended to have a longer time to 
treatment, with a median of 8.3 years [range 4.1–15.6] vs. 5.6 years [2.4–11.9] for EXP 
patients and 4.6 years [2.1–13.7] for the IND category, however this difference was not 
significant across the three groups (P=0.19, Kruskal-Wallis; Supplementary Table 1a). 
Patients with LOG growth (4 of 5) tended to have mutated IGHV, a favourable prognostic 
marker, compared to patients with EXP growth (3 of 10) (P=0.12; Figure 1c).
To examine whether genetic differences underlie the distinct patterns of growth, we 
performed whole-exome sequencing (WES; median coverage of 107X), on a median of 3 
(range 2–6) CLL samples per patient collected prior to receiving therapy, spanning 0.77 to 
10.62 (median 3.28) years between first and last available pre-treatment timepoints 
(Supplementary Table 1b; Supplementary Table 2). Consistent with prior studies12,13, we 
detected a median overall somatic mutation frequency of 0.79/Mb across patients, with 
frequencies of 0.19/Mb of silent events and 0.60/Mb for non-silent sSNVs and 0.031/Mb for 
insertions and deletions (sINDELs) (Supplementary Table 3). In addition, we identified 
somatic copy number alterations (sCNAs) directly from the WES data (Supplementary Table 
4).
By comparing against previously identified putative CLL drivers12,13 (Supplementary Tables 
5 and 6), we identified at least one driver in all 21 patients. We further examined whether the 
detected CLL drivers were clonal or subclonal by inferring their cancer cell fraction (CCF) 
(Methods15). The total number of driver mutations was lowest in patients whose CLLs 
demonstrated LOG growth (median 1, range 1–4) compared to those with IND (median 2, 
range 1–2), or EXP growth (median 4, range 2–7) (P = 0.005). We identified a trend towards 
a higher number of clonal drivers and an increased number of subclonal drivers in samples 
with EXP growth compared to those with LOG or IND growth (P = 0.13 and 0.019, 
respectively). Finally, we saw that, even without therapy, clones with CLL drivers, occurring 
in samples with EXP growth, exhibited larger shifts in their clonal fractions compared to 
ones with IND and LOG growth (P = 0.033; Extended Data Figure 2a–b). Most subclones 
with drivers present at the time of treatment were already detectable in the earliest samples.
Validation of global growth patterns
To confirm these findings, we studied an independent cohort of samples collected from 85 
patients with prior characterization by WES, having at least 4 consecutive pre-treatment 
WBC measurements no more than 2 years apart (Methods)14,15. Unlike the discovery cohort, 
patients in the extension cohort were not specifically selected to have undergone subsequent 
treatment. WES was performed on samples collected at a median of 2.2 years (range 0, 18.9) 
after diagnosis. Of the 38 patients who subsequently underwent treatment, the median time 
from diagnosis to treatment was 2.6 years (range 0, 18.9) (Supplementary Table 7). A 
median of 18 (range 4–73) pre-treatment measurements of circulating WBCs were available 
per patient.
As for the discovery cohort, we classified these 85 patients into LOG, EXP and IND growth 
categories (Methods, Supplementary Table 8). Of 85 CLLs, 43 (51%) showed LOG growth 
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(median estimated CC of 70 × 109 cells/L, range 4–360), 12 showed EXP growth (14%; 
median growth rate 44, range 17–64%), and 30 had IND growth (35%; median growth rate 
33%, range 4–197%) (Figure 2a–c, Extended Data Figure 2c–3). Within CLLs categorized 
as having IND growth, 13 of 30 (43%) had a short period of observation, 15 (50%) had a 
pattern of growth that appeared intermediate between LOG and EXP or was complex; and 2 
(7%) had unevenly distributed data.
Consistent with the results in the discovery cohort, we again found that IGHV mutated status 
was most enriched in patients with LOG growth (P = 0.002). Similarly, we found a 
difference in the number of total, clonal and subclonal drivers among the groups, with larger 
values in patients with EXP growth (P= 0.022, P= 0.011 and P= 0.017, respectively; Figure 
2b, Supplementary Table 7a, Supplementary Table 7b). Even among the 42 patients with 
known IGHV status in the LOG group, the 4 patients with unmutated IGHV had higher CC 
compared to the 38 patients with mutated IGHV (median of 189.2 × 109 vs. 64.4 × 109 
cells/L; P = 0.017). We observed that samples with LOG growth had a higher proportion of 
patients that had either no known driver event or only del(13q) (51% LOG, 24% IND and 
0% EXP; P= 0.001). Also, the EXP group had a higher proportion with trisomy 12 
compared to the IND and LOG cases (42% vs. 10% vs. 9%, P=0.027).
More patients with EXP and IND growth progressed to treatment than those with LOG 
growth (75%, 67%, 21%, P<0.001) (Figure 2d). We modelled the probability of treatment 
using univariable exact logistic regression and stepwise multivariable logistic regression. We 
considered age, sex, growth pattern (EXP vs. LOG, IND vs LOG), IGHV status, FISH 
cytogenetics, number of drivers, and maximum and last available WBC count prior to 
treatment as potential covariates to assess their relative contribution to clinical outcome 
(Methods). In univariable analysis, growth pattern, IGHV status, del(13q), last available 
WBC count and number of total and clonal drivers were significant. The final multivariable 
model included growth rate pattern, del(13q) and last WBC (Extended Data Table 1). 
Growth pattern contributed significantly (for EXP vs LOG: P=0.032; and for IND vs LOG: 
P=0.002) to a model which already included del(13q) and last available WBC count (Figure 
2e).
Growth patterns and evolution of relapse
Since clonal shifts were common in CLLs with more aggressive growth pattern, we asked if 
growth pattern also impacted clonal evolution following therapy. Of the 21 patients in the 
discovery cohort, 12 relapsed (median time from first until next treatment 1.88 years [range 
0.52–5.56]). Ten of these 12 patients had available post-treatment samples, which we also 
characterized by WES.
Six of these 10 patients had clear evidence of clonal evolution, characterized by a significant 
shift in CCF (by 11–100%; Methods) in at least one subclone (Figure 3a, Extended Data 
Figure 4a, Supplementary Table 9). In the other 4 patients, subclones retained interclonal 
balance even after cytoreductive treatment (Figure 3a, Extended Data Figure 4b). In two of 6 
evolving leukaemias, we observed evidence of convergent evolution, with multiple branches 
impacting the same pathway. In Patient 5, clone 5 with GNB1-I80T disappeared, but a 
distinct clone with GNB1-I80N emerged together with a CDKN2A mutation. In Patient 13, 
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one allele of ATM was clonally mutated and the second allele had a distinct subclonal 
mutation of ATM. Following chemotherapy, the mutated ATM subclone was replaced by an 
expanding clone with del(11q) encompassing ATM and BIRC3 on one allele, and two 
mutations in BIRC3 on the other. The 4 other patients with clonal evolution upon relapse 
also revealed emergence of clones with driver events (Extended Data Figure 4). All six 
patients with therapy-related CLL clonal evolution exhibited EXP growth pre-treatment (14–
99%/year). By contrast, those with preserved clonal architecture despite therapy were CLLs 
having either LOG or IND growth (with growth rates <31%/year) (Figure 3a–b, Extended 
Data Figure 4). In patients from our previously reported study,15 we found a similar 
association (Methods, Supplementary Table 1c). Three of the 4 patients with data available 
to evaluate growth patterns had evolving clonal structure upon relapse and an IND or EXP 
growth pattern prior to treatment (growth rates of 32, 64 and 138%/year), while the fourth 
patient with preserved clonal architecture despite therapy exhibited IND growth (Figure 3, 
asterisked bars). Overall, these results support the close association between leukaemia 
growth prior to treatment and clonal evolution following chemotherapy (P=0.003).
Growth patterns of subclones
To identify if distinct growth dynamics could be discerned amongst subclones underlying 
the overall growth patterns, we used information from macroscopic subclones (i.e. having 
CCFs of ≥ 10% at one or more timepoints) to derive likely phylogenies for each patient 
(Methods, Supplementary Table 10, Extended Data Figures 5–7). Using PhylogicNDT18, we 
identified subclones by n-dimensional clustering of CCFs of individual events across 
samples, estimated their phylogenetic relationships and modelled the growth dynamics of 
each subclone (Methods). We focused on the 5 patients with WES from 4 or more pre-
treatment time points (Patients 1, 4, 5, 18, and 19).
Of interest, even with overall LOG growth in the leukaemias of Patients 4, 18 and 19, a 
number of subclones displayed behaviour consistent with EXP growth. Two of 4 subclones 
(clones 1 and 3) of Patient 4 had plateauing growth rates and even decline at the latest time 
point (Figure 4a). By contrast, growth of clone 2 was consistent with EXP growth, providing 
in vivo evidence of competition amongst subclones within an overall picture of LOG growth 
of the bulk tumour. Possibly, the growth pattern of this CLL would become EXP upon 
takeover of the cancer cell population by clone 2. In the other two patients, most clones 
exhibited complex dynamics that did not follow simple exponential or logistic patterns 
(Extended Data Figure 6b). Clone 3 of Patient 19 exhibited mild exponential growth over 
time. The other clones were mostly stable with fluctuations in their abundance. Thus, for 
cases with overall LOG growth, we observed that complex underlying intraclonal dynamics 
can result in net carrying capacity.
Patients 1 and 5, who had CLL with EXP growth, likewise revealed diverse interclonal 
dynamics (Figure 4b, Extended Data Figures 6, 7). The majority of clones in Patient 1 
exhibited EXP growth patterns, with the later subclone (clone 4) showing faster exponential 
growth. In Patient 5, the strongly growing subclones (clones 4 and 5) were only present in 
the last two timepoints, and thus we only tested clones 1–3 for behaviour consistent with 
EXP growth. While the growth pattern of clone 1 did not fit an exponential pattern, both 
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branches (clones 2 and 3) appeared to contribute to the overall EXP growth pattern of this 
case.
For added confidence and validation of WES results, we additionally performed whole-
genome sequencing (WGS) analysis of serial samples from a subset of cases with EXP 
(Patients 1 and 6) and LOG (Patient 4) growth patterns. The WGS results were concordant 
with the WES, while providing narrower credible intervals on the subclonal composition due 
to a ~10-fold higher number of mutations per clone (Methods, Extended Data Figures 8, 9a–
e).
Growth advantage of subclonal drivers
To quantify the growth advantage of individual subclones, we calculated growth rate 
differences (ΔGR) between child and parent clones (Methods). We evaluated whether 
subclonal growth rates differed based on presence or absence of known CLL drivers and if 
they had significant selective advantage compared to the parent clone (Prob[ΔGR>0] > 0.95, 
which corresponds to P<0.05) (Supplementary Table 11). We focused this analysis on the 35 
subclones detected in 16 patients whose leukaemias displayed overall non-logistic WBC 
expansion (since those with overall LOG growth lacked abundant drivers). We inferred the 
distribution of growth rates of individual subclones and the differences to their parents using 
an MCMC algorithm that samples an ensemble of likely phylogenetic trees for each patient 
(PhylogicNDT GrowthKinetics18; Methods). The model also takes into account the reads 
supporting each somatic mutation, tumour purity, absolute copy-number, and the WBC 
measurements (Extended Data Figure 5d).
Indeed, 7 subclones from 6 patients (Patients 1, 5, 6, 9, 13 and 14) contained a known CLL 
driver and their growth was significantly higher compared to their parent subclone (Figure 
5a, Extended Data Figure 9f). The strongest acceleration was associated with a second hit in 
the tumour suppressor genes TP53 or ATM (ΔGR of 127% and 90%/year for clone 4 of 
Patient 1 and clone 2 of Patient 13, respectively). For Patient 14, a subclone with multiple 
driver mutations (XPO1, del(13q) del(15q)) also expanded more rapidly than its parent 
(ΔGR of 57%/year). The CLL of Patient 5 showed high overall growth driven by the two 
independent subclones containing mutations in MED12 and GNB1 (ΔGRs of 41%, and 
78%/year, respectively). We further saw strong growth acceleration in Patient 6 (ASXL1; 
ΔGR of 82%/year) and in Patient 9 (KRAS, ΔGR of 34%/year). These analyses provide an 
in vivo measurement and functional evidence of the cancer driving capacity of these 
mutations. One subclone (from Patient 7) had a growth rate indicative of a fitness advantage 
compared to its parent but without a known CLL driver (Extended Data Figure 9g). Its 
estimated ΔGR was lower than that of subclones with known drivers (ΔGR of 16% (+/
− 10%)/year). Another set of 8 subclones from 4 patients were identified to have mutations 
in known CLL drivers, but lacked significant growth advantage compared to their parent 
subclone (e.g. clone 2 in Patient 3 with mutated CARD11; ΔGR 10%, P=0.20; Extended 
Data Figure 9h). Finally, more than half of the subclones (19 of 35) from 12 patients 
appeared as ‘passenger’ subclones with no relative advantage compared to the parental 
clones and without any known CLL driver. These subclones possibly represent genetic 
drift19,20 or may have had an advantage for a short period of time (e.g. clone 1 in Patient 10, 
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Figure 5b). In 7 of 16 patients, we observed more than one class of subclonal growth 
simultaneously (Extended Data Figure 7). Subclones with known CLL drivers were more 
likely to have accelerated growth relative to their parent (15 clones, median ΔGR of 0.23 
[IQR 0.02 to 0.71]) compared to subclones without additional known drivers (20 clones, 
with median ΔGR of −0.07 [IQR −0.23 to 0.13]; P = 0.013, in a linear mixed model) (Figure 
5c).
Finally, Patients 1, 5, 6, 9, and 13 CLL had subclones with accelerated growth and branched 
phylogenies, providing opportunities for examining relative fitness of drivers within specific 
genetic contexts. For example, acquisition of amp(5q34) and del(17p) in clone 4 (Patient 1) 
appears to confer faster growth than clones with TP53 mutation alone (clone 2), del(11q) 
alone (clone 1) or with FAM50A mutation (clone 3) in the context of clonal SF3B1 
mutation. Likewise, in Patient 6, clone 3 had mutation in ASXL1 in the context of clonal 
del(13q) and del(11p) and expanded faster than a sibling clone having amp(2p) and del(6q). 
With sufficiently large multi-timepoint sequencing datasets and overall tumour burden 
information (i.e. WBC counts), comparing the growth of sibling clones will enable 
constructing a map of fitness of driver events in specific genetic contexts.
Discussion
Many mathematical models have been proposed to describe cancer growth in patients, but 
with no consensus7–9. Previous works reported exponential growth in leukaemia, lung, liver 
and breast cancer7,8, and sigmoidal growth (such as logistic or Gompertz) in earlier studies 
of breast cancer4,5 and in xenografts derived from human colorectal cancer6. Our study 
shows that individual cancers of the same type can exhibit diverse growth patterns: while 
many CLL patients exhibited exponential-like growth with high or unbounded carrying 
capacity, in others, the disease achieved a (potentially temporary) stable state, and exhibited 
a logistic-like pattern with finite carrying capacity. For these distinct growth classes, we 
further identified clear differences in genetic attributes and clinical outcomes: exponential 
growth was associated with a larger number of CLL drivers, greater subclonal dynamics and 
an earlier need for treatment. Conversely, logistic growth was associated with a narrower 
spectrum of genetic alterations, fewer subclonal drivers, and interclonal stability even in 
relapse after treatment. We and others previously noted that del(13q) and trisomy 12 are 
likely early events in CLL phylogeny13,21, and indeed, we found that the presence of 
del(13q) is associated with logistic growth, while trisomy 12 was associated with 
exponential growth. Our multivariable analysis demonstrated that the incorporation of 
growth pattern behaviour provides additional explanatory power above that provided by the 
strong prognostic cytogenetic marker of del(13q) presence17,22, and was stronger than IGHV 
mutational status. Furthermore, the genetic diversity of CLL appears to be established early 
in the disease, consistent with previously reported smaller series23–25. In the absence of 
therapeutic perturbations, the observed rate and pattern of outgrowth of CLL over time thus 
seems to ‘play out’ the pre-determined genetic composition. Of note, the growth rates of 
these clones from untreated patients are several-fold lower than that of relapse clones we 
previously reported in patients receiving ibrutinib2. Recent studies to genetically 
characterize the premalignant states of solid tumours26, and of monoclonal B cell 
lymphocytosis27,28 (considered a precursor condition of CLL), have further supported the 
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idea that the extent of genetic diversity of malignancies like CLL long predates its full-
blown clinical picture.
Our approach of integrating patient tumour burden measurements and sequencing data from 
multiple disease timepoints provides a conceptual framework for understanding the growth 
trajectories of individual populations of CLL cells. We detected evidence of in vivo 
competition amongst subclones in early CLL and more atypical behaviours that could not be 
categorized using simple models, extending previously reported insights on CLL evolution 
during later periods of the disease course29–31. For example, in a subset of patients, we 
observed a shift from overall logistic growth, with many years spent at carrying capacity, to 
exponential growth.
Finally, our computational framework enabled us to quantify the degree of growth 
acceleration and fitness of genetically defined subclones over their parental clones. 
Accelerated growth was strongly enriched in subclones with well-established CLL drivers. 
Thus, we provide clear evidence for the growth-accelerating role and potential synergies of 
driver mutations. We also find frequent existence of growth-neutral subclones without 
drivers, likely representing genetic drift19,20. These fundamental findings are especially 
relevant to the ongoing efforts of precision oncology, where estimation of the clonal growth 
dynamics in individual patients may inform therapy and predict the course of their disease.
Extended Data
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Extended Data Figure 1. Growth kinetics of naturally progressing CLLs from the discovery 
cohort.
a, Time courses of the discovery CLL cohort (Supplementary Table 1). Circles indicate 
timepoints of samples analysed by whole-exome sequencing (WES). Dotted lines represent 
course of CLL from diagnosis (left vertical line) until last follow up (arrows) or death (right 
vertical line) and solid lines indicate timeframe covered by the analysis of serial samples by 
WES, coloured by growth pattern. b, Cumulative distribution function (CDF) of posterior 
probabilities for carrying capacity K obtained from the Bayesian model based on a logistic 
growth pattern for patients. The growth pattern categorizations of the individual patients are 
marked. c, Classification of patients based on probability that their carrying capacity K is 
below 1000 (x 109 white blood cells/L) (red numbers in upper left corner). Also shown are 
the posterior probabilities for all model parameters (carrying capacity K, growth rate r, white 
blood cell counts (WBC) at diagnosis X0 and variance of the noise σ2). Far right panels per 
patient - Leukaemia burden information provided by WBC measurements (blue dots), with 
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ten random fits from the Bayesian model. Red numbers in left upper corners indicate time 
(years) from diagnosis to first treatment.
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Extended Data Figure 2. Growth kinetics of CLLs from the extension cohort.
Shown are samples displaying: a, logistic growth (n = 43), b, indeterminate growth (n= 30) 
or c, exponential growth (n = 12), (information on growth pattern fitting in Supplementary 
Table 8). Blue dots - WBC measurements, coloured lines – ten random growth model fits 
(see Methods). Red numbers in lower left corners indicate years from diagnosis to first 
treatment for patients who progressed to treatment.
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Extended Data Figure 3. Clonal shifts and growth rates in untreated CLL patients.
a, The increase in numbers of total (upper panel), clonal and subclonal drivers (middle and 
bottom panels) is associated with overall leukaemia growth patterns (Kruskal-Wallis test). b, 
A trend towards increased maximal change in the CCF of a driver event is observed between 
the first and last pre-treatment samples of a given patient based on growth pattern (Kruskal-
Wallis). c, Upper panel: Probability for having a carrying capacity K of WBC < 109 cells/L 
(blue dots) for patients with logistic (LOG), indeterminate (IND) or exponential (EXP) 
growth patterns. Bottom panel: Growth rates (small circles) together with 70% credible 
intervals (lines) across the discovery and extension samples, ordered based on probability of 
logistic growth with samples classified as displaying logistic (LOG) growth, indeterminate 
growth (IND) or exponential growth.
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Extended Data Figure 4. Assessment of evolutionary dynamics using sample pairs
Changes of cancer cell fraction (CCF) of subclones represented as two-dimensional pair-
wise plots of multi-sample clustering results. Samples at a timepoint (TP) closest to 
diagnosis (1st) vs the last sample before treatment (preTx) are shown in the left column, 
samples at last timepoint before and first timepoint after treatment are shown in the right 
column. Patients are grouped based on those having: a, subclones with significant evolution 
b, subclones that maintain interclonal balance. Significantly evolving subclones are 
indicated in orange (Methods), expanding CLL driver mutations are labelled (magenta). c, 
Examples of genetic evolution from first to last pre-treatment timepoints, and from pre-
treatment to relapse samples for Patient 6 (with significant evolution) and Patient 10 (not 
evolving). Shown are 2D-distributions that reflect the average of the positional distributions 
of the cluster centres along the MCMC iterations, rather than the final posterior for the 
cluster centre, which is determined by the normalized product of the pre-clustered 
distributions of the mutations that were finally assigned to each cluster. Marginal 
distributions (on the x and y axes) depict the CCF distributions before clustering for each 
individual mutation. Final cluster assignment is indicated by the colour.
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Extended Data Figure 5. Detecting subclones and construction of evolutionary phylogenies using 
simulated data.
a, Bar plots showing the fraction of clustering results on simulated samples that are 
concordant with the ground truth (or differ by ∆n clusters). Simulations are grouped by low 
(2) and high (3–8) number of samples per case as well as low (2–9) and high (≥10) number 
of mutation per subclone. b, Similar CCF accuracy after clustering between simulated WES 
and WGS data. c, Simulation of a case with 5 samples and 5 subclones present at different 
CCF levels per sample (black lines- ground truth). The predicted CCF distributions for each 
cluster are plotted as a function of the number of mutations in the subclone (from 2 to 100). 
When the number of mutations exceeds ~15–20, the CCF predictions become stable and 
accurate (low bias and variance). d, Examples of PhylogicNDT BuildTree algorithm results 
applied to simulated data. Grey shading highlights the correct tree, with percentage of 
MCMC iterations supporting the trees indicated. e, Analysis of prior selection for clustering 
and pigeon-hole principle - For a range of priors with varying mean number of clusters, K, 
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the prior for ⍺ is computed, and the Dirichlet Process posteriors for ⍺ and K illustrate how 
the choice of prior impacts the estimation of K. f, Pigeon-hole principle: for two clusters, A 
and B (top), the convolution (middle) and difference (bottom) is illustrated. The area above 
1.0 CCF of the convolution is consistent with the probability that they are parent-child rather 
than siblings. The area below 0.0 CCF of the difference represents the probability that 
cluster B is more prevalent than cluster A.
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Extended Data Figure 6. Subclonal genetic evolutionary dynamics in the discovery cohort.
a, Subclonal dynamics for each patient in the discovery cohort in relation to tumour load 
over time in the observed disease course (represented by white blood count [WBC], with 
dots indicating an available WBC measurement). Arrows—time of sampling with WES. 
Distinguishable subclones meeting the criteria for confident detection (>10% CCF, in at 
least one sequenced sample) are coloured. CCFs in time periods between sequenced 
timepoints were inferred from the closest sequenced sample. b, Subclonal growth patterns of 
additional patients analogous to Figure 4.
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Extended Data Figure 7. Subclonal growth rate estimates of patients with non-bounded growth.
For 15 patients with non-bounded growth (EXP and IND) and at least one macroscopic 
subclone, we show: (i) first column: selected complete phylogenetic trees of subclones; 
yellow boxes indicate branches that were detectable only in relapse samples. (ii) second 
column: cluster CCF dynamics over time with 95% credible intervals based on uncertainty 
of mutation assignment; (iii) third column: pre-treatment growth rates for each generated 
clone within the most likely phylogeny; (iv) fourth column: relative pre-treatment growth 
rates of subclones compared to their respective parent subclone.
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Extended Data Figure 8. Somatic copy number alteration (sCNA) calling from WES, WGS and 
SNP array data showing highly concordant results
a, results from WES and WGS of CLLs from Patients 1 and 4 and b, in Patient 1 data before 
and after capture bias correction via tangent normalization and c, in TCGA samples with 
available paired WES and SNP array data.
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Extended Data Figure 9. Comparison of PhylogicNDT Clustering results between WES and WGS 
data.
a, In Patient 1, paired results of WES and WGS data were available for all four timepoints 
and demonstrate matching cancer cell fractions (CCFs) throughout. CCF posterior 
distributions for the cluster centres (b) and individual mutations (c) for the corresponding 
subclones found in WES and WGS data of Patient 1. For Patients 4 and 6, two-dimensional 
comparisons are illustrated (d, e). Examples for subclones (magenta boxes) with f, 
significant growth advantage relative to their parent and known driver g, one subclone with 
significantly accelerated growth but no driver and h, subclones with driver and no growth 
acceleration.
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Extended Data Table 1|
Exact logistic regression modelling of the probability of 
treatment.
Models include the 79 of 85 patients having complete data for FISH cytogenetics, IGHV 
mutational status, mutations, and WBC information. From the 85, 6 patients were excluded 
from modeling (n=1 for no sequencing, 1 for missing both IGHV status and FISH 
cytogenetics, 1 for missing IGHV status, and 3 for missing FISH cytogenetics). Final 
multivariable model selected using Stepwise Selection procedure using all variables listed in 
the following table as candidate, resulting P-values are marked by *.
Univariate OR [95% Cl] P-value Final multivariable OR [95% CI] P-value*
N 79 79
Sex, male versus female 0.94 [0.35, 2.49] 1.00
Age ≥ 60 years vs. <60 0.34 [0.10, 1.09] 0.073
EXP vs. LOG 12.89 [2.09, 145.73] 0.003 10.76 [1.18, 154.66] 0.032
IND vs. LOG 6.34 [2.01,21.88] <0.001 8.23 [1.91, 49.37] 0.002
IGHV unmutated vs. mutated 4.74 [1.38.19.17] 0.010
Del(13q) vs. no driver 0.12[0.03, 0.41] <0.001 0.07 [0.01, 0.33] <0.001
Del(17p) vs. no driver 1.21 [0.15, 9.64] 0.99
Trisomy 12 vs. no driver 3.75 [0.81,23.84] 0.10
Number of total drivers
      1 vs. 0 0.50 [0.009, 5.45] 0.95
      2 vs. 0 2.06 [0.44. 9.67] 0.45
      ≥ 3 vs. 0 5 26[1.59,19.05] 0.004
Number of clonal drivers
      1 vs. 0 0 86 [0.16, 3.81] 0.99
      ≥ 2 vs. 0 4.83[1.49,17.26] 0.006
Subclonal driver present vs. absent 2.31 [0.86, 6.39] 0.11
Maximum WBC 1.00 [0.99,1.01] 0.10
Last WBC 1.01 [1.00,1.01]] 0.011 1.01 [1.00, 1.02] <0.001
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Growth dynamics and genetic changes in naturally progressing CLL.
a, Schema of diverse growth patterns observable in CLL samples. b, Illustrative patient 
white blood count (WBC) dynamics over the period between diagnosis and start of 
treatment. c, Putative CLL drivers detected by analysis of whole-exome sequencing (WES) 
analysis of pre-treatment serial samples from 21 patients, with assigned growth patterns, 
IGHV status. Cancer cell fractions (CCF) of mutations are indicated.
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Figure 2. Integrative analysis of global CLL growth patterns and genetic attributes in an 
extension cohort.
a, Examples of logistic (LOG; level of carrying capacity CC) and exponential (EXP; growth 
rate [% per year)] growth patterns (70% credible intervals provided above each graph). 
Arrow indicates that patient received treatment. Red dot – time of WES sampling, b, 
Associations between growth patterns with IGHV status, del(13q) or no driver, trisomy 12 
and numbers of total, clonal and subclonal drivers (two-sided Fisher’s exact test). c, 
Estimated CC (with 70% credible intervals, right axis) for patients with LOG, indeterminate 
(IND) and EXP growth, defined based on probability of CC posteriors (left axis), from 
discovery (red) and extension (black) cohorts, n indicates number of independent patients. d, 
Patients with EXP growth were more likely to require treatment (two-sided Fisher’s exact 
test). e, Exact logistic regression modelling of need for treatment related to growth pattern 
for 79 patients having WES of a pre-treatment sample and FISH data, odds ratio (OR) 
provided with 95% confidence intervals (Extended Data Table 1).
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Figure 3. Treatment-associated evolution in relation to leukaemia growth patterns.
a, Pre-treatment growth pattern for 10 patients of the discovery cohort and 4 previously 
reported patients15 (asterisked) are related to presence (upper group) or absence (bottom 
group) of clonal evolution upon relapse (two-sided Fisher’s exact test). b, Examples of 
integrated WBC dynamics (black dots indicate measurements) and genetic evolution 
between diagnosis and relapse for exponential growth and evolving subclones (Patient 6), or 
indeterminate growth and inter-clonal balance (Patient 10). Colours indicate subclones. 
Arrows indicate timing of samples. Insets—2D visualizations of changes in CCF across 
timepoints (TP).
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Figure 4. Subclonal growth patterns in untreated CLLs.
Subclonal CLL growth patterns, estimated using PhylogicNDT, in overall logistic growth (a) 
and overall exponential growth (b). P-values represent significance of rejecting the null 
hypothesis of exponential growth, based on the proportion of Markov Chain Monte Carlo 
(MCMC) iterations (magenta). The natural logarithms of numbers of cells in each clone 
(WBC/mL) are plotted against years from diagnosis. Error bars and trajectories represent 
uncertainties estimated by the MCMC. Analysis of Patients 5, 18 and 19 in Extended Data 
Figure 6b, and associated WGS analysis in Extended Data Figures 8–9.
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Figure 5. Selective growth advantage of subclones in CLL.
Examples for subclones (magenta circles) with a, significant growth advantage relative to 
their parent and known drivers and b, a subclone without driver and no growth acceleration. 
Results from PhylogicNDT analysis include: most likely phylogenetic tree (left); 
permutations of sSNVs during tree construction yielding posterior CCFs of the clusters 
(with 95% credible intervals) (middle); and growth rates relative to parental clones (right). 
Significance of differential growth rate (ΔGR>0) was estimated based on the MCMC. c, 
Linear mixed model for difference between clones without (n=20) and with (n=15) putative 
CLL drivers. Black outline - significant growth advantage. Horizontal black line indicates 
median values, with whiskers extending to minimum and maximum values on the boxplots.
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